Engineered immune cells take on lupus in first human safety trial
NCT ID NCT06222853
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 23 times
Summary
This early-stage study tests whether a special type of immune cell, called a CAR-T cell, is safe for people with severe lupus that hasn't improved with standard treatments. About 22 participants aged 5 and older will receive these cells and be monitored for side effects and signs of disease improvement. The goal is to see if this approach can control lupus activity without causing serious harm.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Children's Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310052, China
Conditions
Explore the condition pages connected to this study.